Tekmira Pharmaceuticals Corporation Stock Toronto S.E.
Equities
TKM
CA87911B2093
Pharmaceuticals
Sales 2024 * | 11.97M 8.75M | Sales 2025 * | 12.49M 9.14M | Capitalization | 690M 505M |
---|---|---|---|---|---|
Net income 2024 * | -122M -89.27M | Net income 2025 * | -145M -106M | EV / Sales 2024 * | 57.7 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 55.3 x |
P/E ratio 2024 * |
-6.07
x | P/E ratio 2025 * |
-5.11
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.66% |
Latest transcript on Tekmira Pharmaceuticals Corporation
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 14-06-30 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 18-06-10 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 14-11-30 | |
James Meyers
BRD | Director/Board Member | 58 | 18-10-22 |
Daniel Burgess
BRD | Director/Board Member | 62 | 17-03-22 |
1st Jan change | Capi. | |
---|---|---|
-3.65% | 87.06B | |
+2.76% | 40.25B | |
-17.49% | 31.09B | |
+54.44% | 24.74B | |
-13.13% | 15.91B | |
-9.12% | 11.96B | |
-15.45% | 11.92B | |
-42.56% | 11.61B | |
+4.87% | 8.73B |